Inhibition of the mevalonate pathway to override chemoresistance and promote the immunogenic demise of cancer cells: Killing two birds with one stone

Oncoimmunology. 2013 Sep 1;2(9):e25770. doi: 10.4161/onci.25770. Epub 2013 Jul 29.

Abstract

The mevalonate pathway is an attractive target for cancer therapy not only to override multidrug resistance but also to promote the immunogenic demise of malignant cells. Recent data indicate that aminobisphosphonates are superior to statins for the pharmacological manipulation of the mevalonate pathway, since they exert therapeutically relevant effects on both cancer cells and the immune system.

Keywords: calreticulin; immunogenic cell death; mevalonate pathway; multidrug resistance; statins; zoledronic acid; γδ T cells.

Publication types

  • Research Support, Non-U.S. Gov't